Alentis Therapeutics logo
Alentis Therapeutics logo

Alentis Therapeutics

alentis.ch
alentis.ch • 51-200 employees • Founded 2019 • Likely startup • New
51-200 employees • Founded 2019 • Likely startup • New
Actively hiring
Biologics & Biosimilars
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Team
51-200
employees, estimated range
Backers
4
RA Capital Management, Jeito Capital
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2019 Founded
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management fund Jeito Capital fund Longitude Capital fund OrbiMed fund
Similar startupsby what they do, their industry and backers
AngiexVenture round $22M · 13 mo ago • Founded 2015 • 201-500 employees
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Angitia Biopharmaceuticals
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
Tribune TherapeuticsVenture round $40M · 17 mo ago • Founded 2020
Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a…
Evlabio11-50 employees
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody…
Granite Bio AG4 roles
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting…
cAMPfield TherapeuticsFounded 2026 • 3 roles
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…

Overview

THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies.